Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial

Ada S Cheung, Rudolf Hoermann, Jasmine Zhu, Daryl Lim Joon, Jeffrey D Zajac, Mathis Grossmann, Ada S Cheung, Rudolf Hoermann, Jasmine Zhu, Daryl Lim Joon, Jeffrey D Zajac, Mathis Grossmann

Abstract

Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity via its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. In a randomised controlled trial (RCT) of zoledronic acid versus placebo in men commencing extended-duration ADT, we aimed to examine the effects on fat mass and glucose metabolism. We hypothesised that zoledronic acid, which reduces osteocalcin concentrations, would worsen ADT-induced insulin resistance.

Methods: This was a prespecified secondary analysis of an RCT designed to evaluate the effects of zoledronic acid on bone microarchitecture in 76 men with non-metastatic prostate cancer undergoing curative radiotherapy combined with adjuvant ADT (n = 39 randomised to a single dose of zoledronic acid 5 mg, n = 37 randomised to matching placebo). Oral glucose tolerance tests to determine Matsuda Index were performed at 0, 3, 12 and 24 months. Using a mixed model, mean adjusted differences [MAD (95% confidence interval)] between the groups over time are reported.

Results: Over 24 months of ADT, fat mass increased and lean mass decreased for both groups, with no significant between group difference [MAD 401 g (-1307; 2103), p = 0.23 and -184 g (-1325; 955), p = 0.36 respectively]. Bone remodelling markers C-telopeptide [MAD -176 ng/l (-275; -76), p < 0.001 and P1NP -18 mg/l (-32; -5), p < 0.001] as a surrogate for osteocalcin, remained significantly lower in the zoledronic acid group, compared with placebo. There was no mean adjusted between-group difference for homeostatic model assessment 2 insulin resistance (HOMA2-IR) [-0.2 (-0.6; 0.2), p = 0.45], HbA1c [-0.1% (-0.3; 0.1), p = 0.64] or Matsuda Index [0.8 (-1.1; 2.7), p = 0.38]. The Matsuda Index decreased in both groups consistent with worsening insulin resistance with ADT.

Conclusion: A single dose of zoledronic acid does not appear to influence glucose metabolism in men newly commencing ADT. Further study to evaluate the endocrine relationship between bisphosphonates, bone and glucose metabolism is required.

Trial registration number: [ClinicalTrials.gov identifier: NCT01006395].

Keywords: androgen deprivation; bisphosphonates; diabetes; insulin resistance; prostate cancer.

Conflict of interest statement

Conflict of interest statement: Novartis Pharmaceuticals Australia provided ampoules of zoledronic acid (Aclasta®) and matching placebo without cost. Novartis was not involved in the trial design and had no role in the trial design, execution, data analysis, interpretation of the results or writing of the manuscript. The company did not provide financial or any other support beyond provision of drug and placebo.

© The Author(s), 2021.

References

    1. Lee NK, Sowa H, Hinoi E, et al.. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456–469.
    1. Oury F, Sumara G, Sumara O, et al.. Endocrine regulation of male fertility by the skeleton. Cell 2011; 144: 796–809.
    1. Gancheva S, Zhelyazkova-Savova M. Are bisphosphonates associated with adverse metabolic and cognitive effects? A study in intact rats and rats fed high-fat high-fructose diet. Calcif Tissue Int 2020; 107: 41–51.
    1. Yeap BB, Chubb SA, Flicker L, et al.. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010; 163: 265–272.
    1. Pittas AG, Harris SS, Eliades M, et al.. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009; 94: 827–832.
    1. Kumar R, Binkley N, Vella A. Effect of phylloquinone supplementation on glucose homeostasis in humans. Am J Clin Nutr 2010; 92: 1528–1532.
    1. Schafer AL, Sellmeyer DE, Schwartz AV, et al.. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 2011; 96: E1982–E1989.
    1. Johnell O, Scheele WH, Lu Y, et al.. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985–992.
    1. Grey A, Bolland MJ, Wattie D, et al.. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94: 538–544.
    1. Cheung AS, Hoermann R, Dupuis P, et al.. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol 2016; 175: 229–237.
    1. Smith MR, Finkelstein JS, McGovern FJ, et al.. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599–603.
    1. Jhan J-H, Yeh H-C, Chang Y-H, et al.. New-onset diabetes after androgen-deprivation therapy for prostate cancer: a nationwide propensity score-matched four-year longitudinal cohort study. J Diabetes Complications 2018; 32: 688–692.
    1. Chan DC, Yang RS, Ho CH, et al.. The use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus—a population-based cohort study in Taiwan. PLoS One 2015; 10: e0123279.
    1. Toulis KA, Nirantharakumar K, Ryan R, et al.. Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study. J Clin Endocrinol Metab 2015; 100: 1933–1940.
    1. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462.
    1. Cheung AS, Hoermann R, Ghasem-Zadeh A, et al.. Differing effects of zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial. J Bone Miner Res 2020; 35: 1871–1880.
    1. Eidelman E, Twum-Ampofo J, Ansari J, et al.. The metabolic phenotype of prostate cancer. Front Oncol 2017; 7: 131.
    1. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191–2192.
    1. Sikaris K, McLachlan RI, Kazlauskas R, et al.. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90: 5928–5936.
    1. Hamilton EJ, Gianatti E, Strauss BJ, et al.. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377–383.
    1. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, (2019, accessed 14 November 2020).
    1. Bates D, Maechler M, Bolker B, et al.. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67: 1–48.
    1. Cheung AS, Pattison D, Bretherton I, et al.. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology 2013; 1: 583–589.
    1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125–128.
    1. Oesterling JE. Age-specific reference ranges for serum PSA. N Engl J Med 1996; 335: 345–346.
    1. Charlson ME, Pompei P, Ales KL, et al.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
    1. Reid IR, Horne AM, Mihov B, et al.. Zoledronate slows weight loss and maintains fat mass in osteopenic older women: secondary analysis of a randomized controlled trial. Calcif Tissue Int 2020; 106: 386–391.
    1. Hong SH, Koo JW, Hwang JK, et al.. Changes in serum osteocalcin are not associated with changes in glucose or insulin for osteoporotic patients treated with bisphosphonate. J Bone Metab 2013; 20: 37–41.
    1. Karimi Fard M, Aminorroaya A, Kachuei A, et al.. Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: a randomized triple-blind clinical trial. J Diabetes Investig 2019; 10: 731–737.
    1. Moriishi T, Ozasa R, Ishimoto T, et al.. Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet 2020; 16: e1008586.
    1. Diegel CR, Hann S, Ayturk UM, et al.. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet 2020; 16: e1008361.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다